Antidrug antibodies in psoriasis: A systematic review

British Journal of Dermatology

Volumn 170, Issue 2, 2014, Pages 261-273

  Hsu, L ^a   Snodgrass, B T ^a   Armstrong, A W ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODIES; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; BIOLOGICAL FACTORS; DERMATOLOGIC AGENTS; HUMANS; IMMUNOGLOBULIN G; IMMUNOLOGIC FACTORS; IMMUNOSUPPRESSIVE AGENTS; METHOTREXATE; PSORIASIS; RECEPTORS, TUMOR NECROSIS FACTOR;

EID: 84894251636     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/bjd.12654     Document Type: Review

References (64)

1. Kurd SK, Gelfand JM,. The prevalence of previously diagnosed and undiagnosed psoriasis in US adults: results from NHANES 2003-2004. J Am Acad Dermatol 2009; 60: 218-24.
2. Armstrong AW, Harskamp CT, Ledo L, et al,. Coronary artery disease in patients with psoriasis referred for coronary angiography. Am J Cardiol 2012; 109: 976-80.
3. Lee E, Trepicchio WL, Oestreicher JL, et al,. Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris. J Exp Med 2004; 199: 125-30.
4. Ettehadi P, Greaves MW, Wallach D, et al,. Elevated tumour necrosis factor-α (TNF-α) biological activity in psoriatic skin lesions. Clin Exp Immunol 1994; 96: 146-51.
5. Mussi A, Bonifati C, Carducci M, et al,. Serum TNF-α levels correlate with disease severity and are reduced by effective therapy in plaque-type psoriasis. J Biol Regul Homeost Agents 1997; 11: 115-18.
6. Saravolatz LD, Wherry JC, Spooner C, et al,. Clinical safety, tolerability, and pharmacokinetics of murine monoclonal antibody to human tumor necrosis factor-α. J Infect Dis 1994; 169: 214-17.
7. Boulianne GL, Hozumi N, Shulman MJ,. Production of functional chimaeric mouse/human antibody. Nature 1984; 312: 643-6.
8. LoBuglio AF, Wheeler RH, Trang J, et al,. Mouse/human chimeric monoclonal antibody in man: kinetics and immune response. Proc Natl Acad Sci U S A 1989; 86: 4220-4.
9. Harding FA, Stickler MM, Razo J, DuBridge RB,. The immunogenicity of humanized and fully human antibodies: residual immunogenicity resides in the CDR regions. MAbs 2010; 2: 256-65.
10. Kimball AB, Papp KA, Wasfi Y, et al,. Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis treated for up to 5 years in the PHOENIX 1 study. J Eur Acad Dermatol Venereol 2013; 27: 1535-45.
11. Leonardi CL, Powers JL, Matheson RT, et al,. Etanercept as monotherapy in patients with psoriasis. N Engl J Med 2003; 349: 2014-22.
12. Menter A, Tyring SK, Gordon K, et al,. Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial. J Am Acad Dermatol 2008; 58: 106-15.
13. Reich K, Nestle FO, Papp K, et al,. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet 2005; 366: 1367-74.
14. Knight DM, Trinh H, Le J, et al,. Construction and initial characterization of a mouse-human chimeric anti-TNF antibody. Mol Immunol 1993; 30: 1443-53.
15. Mitoma H, Horiuchi T, Tsukamoto H, et al,. Mechanisms for cytotoxic effects of anti-tumor necrosis factor agents on transmembrane tumor necrosis factor α-expressing cells: comparison among infliximab, etanercept, and adalimumab. Arthritis Rheum 2008; 58: 1248-57.
16. Kauffman CL, Aria N, Toichi E, et al,. A phase I study evaluating the safety, pharmacokinetics, and clinical response of a human IL-12 p40 antibody in subjects with plaque psoriasis. J Invest Dermatol 2004; 123: 1037-44.
17. Bartelds GM, Krieckaert CL, Nurmohamed MT, et al,. Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. JAMA 2011; 305: 1460-8.
18. Garces S, Demengeot J, Benito-Garcia E,. The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: a systematic review of the literature with a meta-analysis. Ann Rheum Dis 2013; 72: 1947-55.
19. Baert F, Noman M, Vermeire S, et al,. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 2003; 348: 601-8.
20. Brezinski EA, Armstrong AW,. Off-label biologic regimens in psoriasis: a systematic review of efficacy and safety of dose escalation, reduction, and interrupted biologic therapy. PLOS ONE 2012; 7: e33486.
21. Sivamani RK, Goodarzi H, Garcia MS, et al,. Biologic therapies in the treatment of psoriasis: a comprehensive evidence-based basic science and clinical review and a practical guide to tuberculosis monitoring. Clin Rev Allergy Immunol 2013; 44: 121-40.
22. Armstrong AW, Harskamp CT, Armstrong EJ,. Psoriasis and the risk of diabetes mellitus: a systematic review and meta-analysis. JAMA Dermatol 2013; 149: 84-91.
23. Jadad AR, Moore RA, Carroll D, et al,. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996; 17: 1-12.
24. Stroup DF, Berlin JA, Morton SC, et al,. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 2000; 283: 2008-12.
25. Tyring S, Gordon KB, Poulin Y, et al,. Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis. Arch Dermatol 2007; 143: 719-26.
26. Menter A, Feldman SR, Weinstein GD, et al,. A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis. J Am Acad Dermatol 2007; 56: e1-15.
27. Asahina A, Nakagawa H, Etoh T, et al,. Adalimumab in Japanese patients with moderate to severe chronic plaque psoriasis: efficacy and safety results from a Phase II/III randomized controlled study. J Dermatol 2010; 37: 299-310.
28. Tsai TF, Ho JC, Song M, et al,. Efficacy and safety of ustekinumab for the treatment of moderate-to-severe psoriasis: a phase III, randomized, placebo-controlled trial in Taiwanese and Korean patients (PEARL). J Dermatol Sci 2011; 63: 154-63.
29. Adişen E, Aral A, Aybay C, Gürer MA,. Anti-infliximab antibody status and its relation to clinical response in psoriatic patients: a pilot study. J Dermatol 2010; 37: 708-13.
30. Gottlieb AB, Evans R, Li S, et al,. Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol 2004; 51: 534-42.
31. Gottlieb AB, Kalb RE, Blauvelt A, et al,. The efficacy and safety of infliximab in patients with plaque psoriasis who had an inadequate response to etanercept: results of a prospective, multicenter, open-label study. J Am Acad Dermatol 2012; 67: 642-50.
32. Hoffmann JH, Hartmann M, Enk AH, Hadaschik EN,. Autoantibodies in psoriasis as predictors for loss of response and anti-infliximab antibody induction. Br J Dermatol 2011; 165: 1355-8.
33. Krathen RA, Berthelot CN, Hsu S,. Sustained efficacy and safety of infliximab in psoriasis: a retrospective study of 73 patients. J Drugs Dermatol 2006; 5: 251-4.
34. Takahashi H, Tsuji H, Ishida-Yamamoto A, Iizuka H,. Plasma trough levels of adalimumab and infliximab in terms of clinical efficacy during the treatment of psoriasis. J Dermatol 2013; 40: 39-42.
35. Torii H, Nakagawa H, Japanese Infliximab Study Investigators. Long-term study of infliximab in Japanese patients with plaque psoriasis, psoriatic arthritis, pustular psoriasis and psoriatic erythroderma. J Dermatol 2011; 38: 321-34.
36. Torii H, Nakagawa H, Japanese Infliximab Study Investigators. Infliximab monotherapy in Japanese patients with moderate-to-severe plaque psoriasis and psoriatic arthritis. A randomized, double-blind, placebo-controlled multicenter trial. J Dermatol Sci 2010; 59: 40-9.
37. Papp KA, Tyring S, Lahfa M, et al,. A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. Br J Dermatol 2005; 152: 1304-12.
38. Gordon KB, Gottlieb AB, Leonardi CL, et al,. Clinical response in psoriasis patients discontinued from and then reinitiated on etanercept therapy. J Dermatolog Treat 2006; 17: 9-17.
39. Leonardi C, Strober B, Gottlieb AB, et al,. Long-term safety and efficacy of etanercept in patients with psoriasis: an open-label study. J Drugs Dermatol 2010; 9: 928-37.
40. Mahil SK, Arkir Z, Richards G, et al,. Predicting treatment response in psoriasis using serum levels of adalimumab and etanercept: a single-centre, cohort study. Br J Dermatol 2013; 169: 306-13.
41. Lecluse LL, Driessen RJ, Spuls PI, et al,. Extent and clinical consequences of antibody formation against adalimumab in patients with plaque psoriasis. Arch Dermatol 2010; 146: 127-32.
42. Krueger GG, Langley RG, Leonardi C, et al,. A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. N Engl J Med 2007; 356: 580-92.
43. Papp KA, Langley RG, Lebwohl M, et al,. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 2008; 371: 1675-84.
44. Griffiths CE, Strober BE, van de Kerkhof P, et al,. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N Engl J Med 2010; 362: 118-28.
45. Krieckaert CL, Bartelds GM, Lems WF, Wolbink GJ,. The effect of immunomodulators on the immunogenicity of TNF-blocking therapeutic monoclonal antibodies: a review. Arthritis Res Ther 2010; 12: 217.
46. Hart MH, de Vrieze H, Wouters D, et al,. Differential effect of drug interference in immunogenicity assays. J Immunol Methods 2011; 372: 196-203.
47. Emi Aikawa N, de Carvalho JF, Artur Almeida Silva C, Bonfá E,. Immunogenicity of anti-TNF-α agents in autoimmune diseases. Clin Rev Allergy Immunol 2010; 38: 82-9.
48. Wolbink GJ, Aarden LA, Dijkmans BA,. Dealing with immunogenicity of biologicals: assessment and clinical relevance. Curr Opin Rheumatol 2009; 21: 211-15.
49. van Schouwenburg PA, van de Stadt LA, de Jong RN, et al,. Adalimumab elicits a restricted anti-idiotypic antibody response in autoimmune patients resulting in functional neutralisation. Ann Rheum Dis 2013; 72: 104-9.
50. Svenson M, Geborek P, Saxne T, Bendtzen K,. Monitoring patients treated with anti-TNF-α biopharmaceuticals: assessing serum infliximab and anti-infliximab antibodies. Rheumatology (Oxford) 2007; 46: 1828-34.
51. Dore RK, Mathews S, Schechtman J, et al,. The immunogenicity, safety, and efficacy of etanercept liquid administered once weekly in patients with rheumatoid arthritis. Clin Exp Rheumatol 2007; 25: 40-6.
52. Keystone EC, Schiff MH, Kremer JM, et al,. Once-weekly administration of 50 mg etanercept in patients with active rheumatoid arthritis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2004; 50: 353-63.
53. Bartelds GM, Wijbrandts CA, Nurmohamed MT, et al,. Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. Ann Rheum Dis 2007; 66: 921-6.
54. Bender NK, Heilig CE, Dröll B, et al,. Immunogenicity, efficacy and adverse events of adalimumab in RA patients. Rheumatol Int 2007; 27: 269-74.
55. Gottlieb A, Menter A, Mendelsohn A, et al,. Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial. Lancet 2009; 373: 633-40.
56. Sandborn WJ, Gasink C, Gao LL, et al,. Ustekinumab induction and maintenance therapy in refractory Crohn's disease. N Engl J Med 2012; 367: 1519-28.
57. Rojas JR, Taylor RP, Cunningham MR, et al,. Formation, distribution, and elimination of infliximab and anti-infliximab immune complexes in cynomolgus monkeys. J Pharmacol Exp Ther 2005; 313: 578-85.
58. Maini RN, Breedveld FC, Kalden JR, et al,. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor α monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998; 41: 1552-63.
59. Vermeire S, Noman M, Van Assche G, et al,. Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease. Gut 2007; 56: 1226-31.
60. Weinblatt ME, Keystone EC, Furst DE, et al,. Adalimumab, a fully human anti-tumor necrosis factor α monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 2003; 48: 35-45.
61. Zachariae C, Mork NJ, Reunala T, et al,. The combination of etanercept and methotrexate increases the effectiveness of treatment in active psoriasis despite inadequate effect of methotrexate therapy. Acta Derm Venereol 2008; 88: 495-501.
62. Maneiro JR, Salgado E, Gomez-Reino JJ,. Immunogenicity of monoclonal antibodies against tumor necrosis factor used in chronic immune-mediated inflammatory conditions: systematic review and meta-analysis. JAMA Intern Med 2013; 173: 1-13.
63. de Vries MK, van der Horst-Bruinsma IE, Nurmohamed MT, et al,. Immunogenicity does not influence treatment with etanercept in patients with ankylosing spondylitis. Ann Rheum Dis 2009; 68: 531-5.
64. Arends S, Lebbink HR, Spoorenberg A, et al,. The formation of autoantibodies and antibodies to TNF-α blocking agents in relation to clinical response in patients with ankylosing spondylitis. Clin Exp Rheumatol 2010; 28: 661-8.